October 22, 2020 10:14 AM EDT
Financing
Startups
Cell/Gene Tx

Can B cells break the bound­aries of cell ther­a­py? Long­wood start­up has $52M to prove a new en­gi­neer­ing tech

Amber Tong

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Take­da an­nounces hand­ful of pipeline cuts in ef­fort to ‘piv­ot re­sources’

GSK awaits Nu­cala de­ci­sion af­ter FDA tar­get date pass­es

AI-fo­cused biotech in­sitro cuts 22% of staff, cit­ing 'tu­mul­tuous mar­ket'

'Find a way, or make one': How two sci­en­tists hope to re­vi­tal­ize CRISPR's rare dis­ease cri­sis

As­traZeneca los­es ap­peals court fight over IRA drug price ne­go­ti­a­tions

sponsored

In one of the riski­est in­dus­tries — Biotech — a sure­fire way to neu­tral­ize some of that risk emerges

A service from the Financial Times